Low Dose Dasatinib Is Not As Active in a CML CP Cohort Enriched with Intermediate/High-Risk CML Chronic Phase: A Phase IIb Multi-Center Trial

Abraham, Aby; Jain, Hasmukh; Bhattacharyya, Jayanta; Dubashi, Biswajit; PK, Jayachandran; Bhurani, Dinesh; Bala, Stalin; Pramanik, Suman; Devadas, Santhosh Kumar; Kulkarni, Uday; Sengar, Manju; Ahmed, Rayaz; Mani, Thenmozhi; Das, Damodar; Karunakaran, Parathan; Gundeti, Sadashivudu; Pallasseri, Rasmi; Patkar, Nikhil; Nookala, Manjunath; Kayal, Smita; Balasubramanian, Poonkuzhali

doi:10.1182/blood-2022-169777

Cited by 2 publications

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…9 Lastly, extrapolating from accruing evidence of low doses of dasatinib in individuals with intact guts may support that in SBS, even if bioavailability is incomplete due to altered gut anatomy, the effective dose may still provide a clinically meaningful response. 2,[20][21][22][23] As a reference, the DASISION trial investigating standard dose dasatinib 100 mg once daily had a 3-month BCR::ABL1 (IS) transcript level of ≤10% in 84% of patients. 24 Several trials accessed lower doses of dasatinib assessing potential efficacy while mitigating safety concerns and had positive results with BCR::ABL1 reductions (Table 2).…”

Section: Discussionmentioning

confidence: 99%

Successful dasatinib therapy in newly diagnosed chronic myeloid leukemia in the setting of short bowel syndrome

Freydman

Staron

Hughes

et al. 2023

J Oncol Pharm Pract

View full text Add to dashboard Cite

Introduction: There is limited guidance on the selection of tyrosine kinase inhibitors (TKIs) in patients with short bowel syndrome (SBS). Concerns regarding absorption, toxicity profiles, and drug interactions should be considered when selecting optimal TKI therapy. Case Report: A 57-year-old male with SBS was newly diagnosed with chronic myeloid leukemia (CML). A careful review of his surgical history, comorbidities, and concurrent medications led to a treatment decision to initiate dasatinib at 100 mg once daily. Management and Outcome: After initiation of therapy, the patient achieved a complete hematological response after two weeks and an early major molecular response on a three-month assessment. The therapy was tolerated well with no identified adverse effects. Discussion: Clinical rationale for selecting dasatinib in patients with SBS includes supporting literature regarding its pharmacokinetic absorption characteristics, its efficacy with lower doses in newly diagnosed patients with CML, and its side effect profile in comparison to other second-generation TKIs. The case discussed provides an example of successful therapy in a patient with SBS undergoing treatment for CML.

show abstract

Section: Discussionmentioning

confidence: 99%

Successful dasatinib therapy in newly diagnosed chronic myeloid leukemia in the setting of short bowel syndrome

Freydman

Staron

Hughes

et al. 2023

J Oncol Pharm Pract

View full text Add to dashboard Cite

show abstract

Treatment-Free Remission in Chronic Myeloid Leukemia

Bourne,

Bhatia,

Jamy

2024

JCM

View full text Add to dashboard Cite

With the discovery of tyrosine kinase inhibitors (TKIs), overall survival in patients with chronic myeloid leukemia (CML) now approaches that of the general population. While these TKIs have proven to be lifesaving, remaining on them lifelong creates both physical and financial burdens for patients. Recently, multiple trials have begun looking into the efficacy of trialing patients off these TKIs to see if they can sustain treatment-free remission (TFR). TFR eligibility is currently limited to a small population of patients with both robust and sustained responses to TKIs. Currently, for those who attempt a trial of TFR, the average success rates are promising, with anywhere from 38 to 54% of patients experiencing sustained TFR. For those who fail to maintain sustained TFR, safety results to date are reassuring, with almost all patients successfully responding to the re-initiation of TKIs, with death and disease progression being very rare complications. Moving forward, research is being conducted to more accurately risk stratify patients at diagnosis and pair them with optimized upfront treatment regimens aimed at increasing candidacy for the trial of TFR.

show abstract

Low Dose Dasatinib Is Not As Active in a CML CP Cohort Enriched with Intermediate/High-Risk CML Chronic Phase: A Phase IIb Multi-Center Trial

Cited by 2 publications

References 0 publications

Successful dasatinib therapy in newly diagnosed chronic myeloid leukemia in the setting of short bowel syndrome

Successful dasatinib therapy in newly diagnosed chronic myeloid leukemia in the setting of short bowel syndrome

Treatment-Free Remission in Chronic Myeloid Leukemia

Contact Info

Product

Resources

About